Clene Inc. — Director's Dealing 2021

Jan 4, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Clene Inc. (CLNN)
CIK: 0001822791
Period of Report: 2020-12-30

Reporting Person: Etherington Robert Dee (N/A)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Incentive Stock Option (right to buy)	$0.5039		Common Stock (428674.00)		Direct
Incentive Stock Option (right to buy)	$0.144		Common Stock (1092777.00)		Direct

Footnotes

F1: Awarded under the Clene Nanomedicine, Inc. 2014 Stock Plan on November 23, 2015 and currently exercisable. The options will expire 10 years from the date of the grant.

F2: Awarded under the Clene Nanomedicine, Inc. 2014 Stock Plan on July 31, 2014 and currently exercisable. The options expire 10 years from the date of the grant.